Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Bi-nanobody) is designed to be expressed as a VHH from anti-CD64 antibody variable domains fused with a VHH from an anti-EGFR antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.